DK2480220T3 - Behandling og forebyggelse af HIV-infektion - Google Patents
Behandling og forebyggelse af HIV-infektion Download PDFInfo
- Publication number
- DK2480220T3 DK2480220T3 DK10762626.9T DK10762626T DK2480220T3 DK 2480220 T3 DK2480220 T3 DK 2480220T3 DK 10762626 T DK10762626 T DK 10762626T DK 2480220 T3 DK2480220 T3 DK 2480220T3
- Authority
- DK
- Denmark
- Prior art keywords
- brecanavir
- administration
- hiv
- formulation
- months
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Anvendelse af en parenteral formulering, der omfatter en antiviralt effektiv mængde af brecanavir eller et farmaceutisk acceptabelt syreadditionssalt deraf og et bæremateriale uden et yderligere middel, der har en positiv virkning på lægemiddelmetabolismen og/eller farmakokinetikken til forbedring af biotilgængeligheden, hvor det yderligere middel er ritonavir, til fremstilling af et medikament til behandling af et individ, der er inficeret med HIV, hvor formuleringen er til intermitterende administration ved hjælp af subkutan eller intramuskulær injektion med et tidsinterval fra to uger til ét år.
2. Anvendelse ifølge krav 1, hvor den parenterale formulering er en opløsning, der omfatter en effektiv mængde af brecanavir og et vandigt bæremateriale.
3. Anvendelse ifølge krav 2, hvor et opløsningsmiddel eller overfladeaktivt stof er tilsat til opløsningen.
4. Anvendelse ifølge et hvilket som helst af kravene 1-3, hvor formuleringen er til administration med et tidsinterval fra to uger til én måned.
5. Anvendelse ifølge et hvilket som helst af kravene 1-3, hvor formuleringen er til administration med et tidsinterval fra én måned til tre måneder.
6. Anvendelse ifølge et hvilket som helst af kravene 1-3, hvor formuleringen er til administration med et tidsinterval fra tre måneder til seks måneder.
7. Anvendelse ifølge et hvilket som helst af kravene 1-3, hvor formuleringen er til administration en gang hver måned.
8. Anvendelse ifølge et hvilket som helst af kravene 1-3, hvor formuleringen er til administration en gang hver 3. måned.
9. Anvendelse ifølge krav 1, hvor blodplasmaniveauet holdes på et niveau over 28 ng/ml.
10. Farmaceutisk præparat til administration ved hjælp af intramuskulær eller subkutan injektion, der omfatter en terapeutisk effektiv mængde af brecanavir eller et salt deraf, i form af en suspension af mikro- eller nanopartikler, der omfatter: (a) brecanavir eller et salt deraf i mikro- eller nanopartikelform, der har en overflademodulator adsorberet til overfladen deraf; og (b) et farmaceutisk acceptabelt, vandigt bæremateriale; hvori den aktive bestanddel brecanavir er suspenderet.
11. Præparat ifølge krav 10, hvor overflademodulatoren er udvalgt blandt poloxamerer, a- tocopherylpolyethylenglycolsuccinater, polyoxyethylensorbitanfedtsyreestere og salte af negativt ladede phospholipider.
12. Præparat ifølge krav 10 eller 11, hvor overflademodulatoren er udvalgt blandt poloxamer 338, Vitamin E-TGPS, polysorbat-80, polysorbat-20 og æg- phosphatidylglycerolnatrium.
13. Præparat ifølge et hvilket som helst af kravene 10 til 12, hvor den gennemsnitlige effektive partikelstørrelse af brecanavir-mikro- eller nanopartikler er under 200 nm.
14. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor den parenterale formulering er et farmaceutisk præparat ifølge et hvilket som helst af kravene 10 til 13.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170916 | 2009-09-22 | ||
| PCT/EP2010/063930 WO2011036159A2 (en) | 2009-09-22 | 2010-09-22 | Treatment and prevention of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2480220T3 true DK2480220T3 (da) | 2015-02-23 |
Family
ID=41466671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10762626.9T DK2480220T3 (da) | 2009-09-22 | 2010-09-22 | Behandling og forebyggelse af HIV-infektion |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20120201868A1 (da) |
| EP (1) | EP2480220B1 (da) |
| JP (1) | JP5897465B2 (da) |
| KR (2) | KR101845811B1 (da) |
| CN (1) | CN102573815B (da) |
| AU (1) | AU2010299959B2 (da) |
| BR (1) | BR112012006345A2 (da) |
| CA (1) | CA2774750C (da) |
| DK (1) | DK2480220T3 (da) |
| ES (1) | ES2530941T3 (da) |
| HK (1) | HK1174256A1 (da) |
| HR (1) | HRP20150192T1 (da) |
| MX (1) | MX2012003424A (da) |
| PL (1) | PL2480220T3 (da) |
| RU (1) | RU2569058C2 (da) |
| WO (1) | WO2011036159A2 (da) |
| ZA (1) | ZA201202070B (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4037661A1 (en) * | 2019-10-01 | 2022-08-10 | VIIV Healthcare Company | Method for treating hiv with cabotegravir and rilpivirine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| AR031520A1 (es) | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
| US7220768B2 (en) * | 2003-02-11 | 2007-05-22 | Wyeth Holdings Corp. | Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus |
| BRPI0707179A2 (pt) * | 2006-01-20 | 2011-04-26 | Tibotec Pharm Ltd | tratamento de longo termo de infecção por hiv |
| AU2008274185B2 (en) * | 2007-07-12 | 2014-07-03 | Janssen Sciences Ireland Uc | Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
-
2010
- 2010-09-22 US US13/497,719 patent/US20120201868A1/en not_active Abandoned
- 2010-09-22 MX MX2012003424A patent/MX2012003424A/es active IP Right Grant
- 2010-09-22 RU RU2012116070/15A patent/RU2569058C2/ru active
- 2010-09-22 JP JP2012529305A patent/JP5897465B2/ja active Active
- 2010-09-22 BR BR112012006345-6A patent/BR112012006345A2/pt not_active Application Discontinuation
- 2010-09-22 KR KR1020177036213A patent/KR101845811B1/ko active IP Right Grant
- 2010-09-22 PL PL10762626T patent/PL2480220T3/pl unknown
- 2010-09-22 CA CA2774750A patent/CA2774750C/en active Active
- 2010-09-22 WO PCT/EP2010/063930 patent/WO2011036159A2/en active Application Filing
- 2010-09-22 KR KR1020127008150A patent/KR101811314B1/ko active IP Right Grant
- 2010-09-22 EP EP10762626.9A patent/EP2480220B1/en active Active
- 2010-09-22 AU AU2010299959A patent/AU2010299959B2/en not_active Ceased
- 2010-09-22 ES ES10762626T patent/ES2530941T3/es active Active
- 2010-09-22 DK DK10762626.9T patent/DK2480220T3/da active
- 2010-09-22 CN CN201080042909.3A patent/CN102573815B/zh active Active
-
2012
- 2012-03-20 ZA ZA2012/02070A patent/ZA201202070B/en unknown
-
2013
- 2013-01-29 HK HK13101244.7A patent/HK1174256A1/xx not_active IP Right Cessation
-
2015
- 2015-02-19 HR HRP20150192AT patent/HRP20150192T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1174256A1 (en) | 2013-06-07 |
| CN102573815B (zh) | 2015-09-30 |
| RU2012116070A (ru) | 2013-10-27 |
| KR20120093850A (ko) | 2012-08-23 |
| WO2011036159A2 (en) | 2011-03-31 |
| US20120201868A1 (en) | 2012-08-09 |
| KR20170141825A (ko) | 2017-12-26 |
| EP2480220A2 (en) | 2012-08-01 |
| CA2774750A1 (en) | 2011-03-31 |
| MX2012003424A (es) | 2012-05-08 |
| RU2569058C2 (ru) | 2015-11-20 |
| KR101845811B1 (ko) | 2018-05-18 |
| AU2010299959B2 (en) | 2016-07-21 |
| ZA201202070B (en) | 2013-08-28 |
| JP2013505224A (ja) | 2013-02-14 |
| PL2480220T3 (pl) | 2015-10-30 |
| ES2530941T3 (es) | 2015-03-09 |
| WO2011036159A3 (en) | 2011-11-24 |
| AU2010299959A1 (en) | 2012-03-01 |
| CA2774750C (en) | 2017-11-28 |
| HRP20150192T1 (hr) | 2015-04-10 |
| EP2480220B1 (en) | 2014-11-19 |
| JP5897465B2 (ja) | 2016-03-30 |
| KR101811314B1 (ko) | 2017-12-26 |
| CN102573815A (zh) | 2012-07-11 |
| BR112012006345A2 (pt) | 2020-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2662068T3 (es) | Suspensiones acuosas de TMC278 | |
| CA2961528A1 (en) | Long acting pharmaceutical compositions | |
| DK2480220T3 (da) | Behandling og forebyggelse af HIV-infektion | |
| AU2016219555B2 (en) | Aqueous suspensions of TMC278 | |
| US20230405001A1 (en) | Treatment or prevention of hiv infection | |
| WO2023222754A1 (en) | Rilpivirine for use in the treatment or prevention of hiv infection |